Lakewood-Amedex Biotherapeutics, Inc. (LABT)
2.69
-0.61
(-18.48%)
USD |
NASDAQ |
Jul 02, 16:00
2.74
+0.05
(+1.86%)
After-Hours: 20:00
Lakewood-Amedex Biotherapeutics Enterprise Value : 4.072M for July 1, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| July 01, 2026 | 4.072M |
| June 30, 2026 | 3.959M |
| June 29, 2026 | 4.199M |
| June 26, 2026 | 4.220M |
| June 25, 2026 | 4.163M |
| June 24, 2026 | 4.368M |
| June 23, 2026 | 4.544M |
| June 22, 2026 | 4.318M |
| June 18, 2026 | 4.467M |
| June 17, 2026 | 5.989M |
| June 16, 2026 | 6.917M |
| June 15, 2026 | 6.952M |
| June 12, 2026 | 7.152M |
| June 11, 2026 | 6.838M |
| June 10, 2026 | 7.091M |
| June 09, 2026 | 6.538M |
| June 08, 2026 | 6.257M |
| June 05, 2026 | 6.452M |
| June 04, 2026 | 6.502M |
| June 03, 2026 | 6.304M |
| June 02, 2026 | 6.114M |
| June 01, 2026 | 6.325M |
| May 29, 2026 | 6.502M |
| May 28, 2026 | 6.888M |
| May 27, 2026 | 6.912M |
| Date | Value |
|---|---|
| May 26, 2026 | 6.762M |
| May 22, 2026 | 6.724M |
| May 21, 2026 | 7.169M |
| May 20, 2026 | 7.051M |
| May 19, 2026 | 7.851M |
| May 18, 2026 | 8.440M |
| May 15, 2026 | 12.31M |
| May 14, 2026 | 15.55M |
| May 13, 2026 | 22.52M |
| May 12, 2026 | 24.43M |
| May 11, 2026 | 24.00M |
| May 08, 2026 | 23.58M |
| May 07, 2026 | 24.99M |
| May 06, 2026 | 23.79M |
| May 05, 2026 | 23.58M |
| May 04, 2026 | 24.71M |
| May 01, 2026 | 25.91M |
| April 30, 2026 | 20.48M |
| April 29, 2026 | 27.03M |
| April 28, 2026 | 29.14M |
| April 27, 2026 | 27.52M |
| April 24, 2026 | 53.51M |
| April 23, 2026 | 62.67M |
| April 22, 2026 | 58.09M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 10.88B |
| Oncolytics Biotech, Inc. | 99.61M |
| Sangamo Therapeutics, Inc. | 15.36M |
| Sarepta Therapeutics, Inc. | 2.305B |
| Anixa Biosciences, Inc. | 91.76M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.9233M |
| Total Expenses (Quarterly) | 0.9233M |
| EPS Diluted (Quarterly) | -2.00 |
| Earnings Yield | -327.1% |